DIAGNOSIS OF HEART FAILURE Aaron Sverdlov
Transcript of DIAGNOSIS OF HEART FAILURE Aaron Sverdlov
DIAGNOSIS OF HEART FAILURE
Aaron SverdlovMBBS PhD FRACP FCSANZ FESC FHFA FACC
Heart Foundation Future Leader Fellow
Associate Professor & Director of Heart Failure
• University of Newcastle & HMRI
Clinical Lead
• Heart Failure Service HNELHD
1
Outline• Definition of Heart Failure• Burden of Heart Failure• Types of Heart Failure and why do we care• Diagnosis of Heart Failure• Important co-morbidities to consider
2
Definition
3
HF is a clinical syndrome characterized by typical
symptoms (e.g. breathlessness, ankle swelling and fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure, pulmonarycrackles and peripheral oedema) caused by a structural and/or functional cardiac abnormality, resulting in a reduced cardiac output and/or
elevated intracardiac pressures at rest or during stress.
Ponikowski P et al, Eur Heart J 2016; 37, 2129–2200
HF represents global health burden
4
HF is common and the prevalence is
growing
6
• 1 in 5 people aged 40 years and over will develop heart failure in their lifetime1
• It is the most rapidly growing cardiovascular condition2,3
• Prevalence of HF is predicted to increase in developed countries because of ageing populations: in the US is estimated to increase by 46% between 2012-20304
Projections of HF prevalence in the US (2010-2030)4
2010 2015 2020 2025 2030
Year
Pre
vale
nce
of H
F %
HF= heart failure.1. Lloyd-Jones DM, et al. Circulation. 2002;106(24):3068-72; 2. McMurray JJV, Stewart S. Eur Heart J Suppl. 2002;4:D50–D58; 3. Ponikowski, P, et al. ESC 2014. Available at: http://www.escardio.org/communities/HFA/Documents/whfa-whitepaper.pdf; 4. Heidenreich PA, et al. Circulation. 2013;6:606-619.
46%
2.8
3.0
3.1
3.33.5
Australian data
7
Additional 536,000 with
HFPEF
NSW burden of Heart Failure
8
Probability of survival with HF compared to 4 common cancers
9
10
• Approx 2000 admissions per annum• 69% annual re-admission or death• 29% 30-day re-admission or death• 50% mortality at 2.7 years• 20% 30-day re-admission rate
Not decreasing over time
11
Australian statistics
12
Australian Institute of Health and Welfare:Bulletin 141; September 2017 Trends in cardiovascular deaths
Why is heart failure such a serious problem?
Heart Failure is a price we pay for the successful
treatment of other forms of heart disease
• Most successful treatments of heart disease do not CURE heart disease• ACS• Chronic CAD• Hypertension• Valvular heart disease• Congenital heart disease
13
Classification of Heart Failure - I
14
Ponikowski P et al, Eur Heart J 2016; 37, 2129–2200
Classification of Heart Failure - II
15
Yancy CW et al, JACC 2013; 62:1495-539
Why is classification important?Newest guidelines
16
ESC Heart Failure Guidelines for HFrEF (2016)
HFREF – Heart failure with reduced ejection fraction (EF<40%)1. Ponikowski P et al. Eur Heart J 2016.
17
Treatment of HFpEF
18
• “No treatment has yet been shown, convincingly, to reduce morbidity and mortality in patients with HFPEF”.
Diuretics are used to control sodium and water retention and relieve breathlessness and oedema. Adequate treatment of hypertension and myocardial ischaemia is also considered to be important, as is control of the ventricular rate in patients with AF.
ESC Guidelines. European Heart Journal (2016) 37,2129-2200.
• 2166 patients followed over 3 years
• 62% HFrEF
• 38% HFpEF
• 16.2% had HFpEF with previous
evidence of LVEF < 40%
19
Kalogeropoulos, A. et al. JAMA Cardiology 2016;1(5):510-518
HFpEF: Disease on the rise
20
Shah SJ, Curr Heart Fail Rep 2013; 10(4): 401-10
N=110,621 patients hospitalized with HF;P<0.0001 for trend of increased HFpEF prevalence*
Proposed mechanisms
Altered calcium signaling
Impaired energetics
Altered matrix
Altered titin fx
Altered sarcomeric fx
Etc, etc
Metabolic syndrome
ObesityDiabetes
Hypertension
Increased TG
Decreased HDL
HFpEF: Clinical causes and mechanisms
Adapted from Shah, A. M. & Pfeffer, M. A. (2012) Nat. Rev. Cardiol. doi:10.1038/nrcardio.2012.1230
Diastolic dysfunctionLeft ventricular hypertrophy
Energetic Impairment
21
HFpEF: SurvivalDismal survival rate at 5 years after heart failure hospitalization, significantly worse for elderly patients
22
Owan T et al. N Engl J Med 2006;355:251-259
35% survival at 5 years after HF hospitalization, regardless of LVEF
20
25
30
35
40
45
50
55
60
50 55 60 65 70 75 80 85
Pre
dic
ted
% m
ort
alit
y w
ith
in 3
ye
ars
Age (years)
EF:40+
EF:<30
Mortality rate increases with age, especially in patients with EF > 40
Pocock et al Eur. Hart J 2013; 34 1404-1413
HFpEF: NOTHING WORKS WELL
23
24
Ponikowski P et al, Eur Heart J 2016; 37, 2129–2200
Definition
25
HF is a clinical syndrome characterized by typical
symptoms (e.g. breathlessness, ankle swelling and fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure, pulmonarycrackles and peripheral oedema) caused by a structural and/or functional cardiac abnormality, resulting in a reduced cardiac output and/or
elevated intracardiac pressures at rest or during stress.
Ponikowski P et al, Eur Heart J 2016; 37, 2129–2200
Key features of a heart failure diagnosis
• IS IT HF & WHY?
• WHAT TYPE?
• WHY NOW?
• SEVERITY?
26
How do we diagnose heart failure?27
Ponikowski P et al, Eur Heart J 2016; 37, 2129–2200
Breathlessness is
almost universal
Consider aetiologies of heart failure28
Ponikowski P et al, Eur Heart J 2016; 37, 2129–2200
Diagnostic algorithm for non-acute HF29
Ponikowski P et al, Eur Heart J 2016; 37, 2129–2200
Natriuretic peptide evidence
30
Roberts E et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ 2015;350:h910.
2016 ESC Key diagnostic criteria for HFpEF
• Preserved EF
• Structural alterations
• Functional alterations
• Natriuretic peptides
• ≥ 50%
• LAVI > 34ml/m2 or• LVMI ≥ 115 (M)/ ≥95 (F)
• E/e` ≥ 13• e` < 9 cm/s
• NT-proBNP > 125pg/ml or• BNP > 35pg/ml
31
Ponikowski P et al, Eur Heart J 2016; 37, 2129–2200
32
Presented by Prof Burkert Pieske at Heart Failure 2018, Vienna, Austria on 28th of May 2018
Key diagnostic imaging tests in non-acute setting• CXR – predominantly only useful for diagnosis of alternative
causes• Echocardiography – single most useful diagnostic test in
Heart Failure• Systolic and diastolic function• Evidence of past MIs• Valvular function• Pulmonary pressures/RV function
• Stress testing/CTCA – to exclude ischaemic aetiology• CMR – gold standard for volumes, mass and EF. Indicated
where good quality echo cannot be obtained and for certain specific causes of HF (infiltrative/non-compaction/Fabry etc)
33
Ponikowski P et al, Eur Heart J 2016; 37, 2129–2200Yancy CW et al, JACC 2013; 62:1495-539
Other tests to address: Why Now?Ischaemia / ACSArrhythmiaUncontrolled hypertensionInfectionWorsening renal failureAdverse medication usage (NSAIDs)Non-complianceNon-pharmacological (salt, fluid, alcohol) MedicationsOther (anaemia)
34
35
Ponikowski P et al, Eur Heart J 2016; 37, 2129–2200
36
37
38
39
40
41
42
Comorbidities among chronic conditions
43
HFpEF: Projected burden of risk factors
44
Common & commonly forgotten comorbidities
• Hypertension• Coronary Artery Disease • Renal failure• Obesity• Diabetes• Thyroid dysfunction• Iron deficiency• Sleep apnoea
45
Iron Supplementation in HF• Iron deficiency is associated with a worse prognosis• Only IV ferric carboxymaltose has been shown to be effective!• FAIR-HF: improvement in NYHA class and global assessment• CONFIRM-HF: improvement in exercise capacity &
hospitalization
46
61%
Anker SD, et al. N Engl J Med 2009;361:2436–2448Ponikowski P, et al. Eur Heart J. 2015;36:657-68.Jankowska EA ,et al. Eur Heart J 2014; 35:2468–2476
Yancy et al. 2017 ACC/AHA/HFSA focused update to the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017
Sleep apnoea in HF
48
Khayat R, et al. Eur Heart J 2015;36:1463–1469.
Adaptive servo-ventilation for CSA in HFrEF
49
Angermann C, et al. N Engl J Med 2015;373:1095–1105.
Sleep apnoea50
Yancy et al. 2017 ACC/AHA/HFSA focused update to the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017
Summary I
• HF is common with various aetiologies, leading to a global burden and significant medical costs
• Despite improvements in overall CVD mortality, outcomes for patients with HF are poor and have not improved in the last decade
• HF prevalence is on the rise mainly due to HFpEF• HFpEF is not easy to diagnose and even harder to treat• Identification and management of co-morbidities is paramount
51
Summary – Diagnosis 101The key components of HF diagnosis are:• Thorough history including attention to:
• Potential aetiologies of HF• Conditions know to co-exist frequently with HF• Conditions which can precipitate HF
• Physical examination• ECG & CXR (more useful in acute HF)• Natriuretic peptides if available (and may reduce
unnecessary echocardiography)• Echocardiography, echocardiography,
echocardiography
• Advanced assessment, including access to Cardiologists, CMR, CPET, Cathlab
52